
Chinese vaccine manufacturers Sinopharm claim that it’s vaccines can create strong antibodies against the new ‘Delta’ variant of COVID-19
This is according to a report from Global Times.
Chinese researchers led by Yang Xiaoming, chairman of Sinopharm China National Biotec Group, a subsidiary of Sinopharm, have found that its vaccine, Sinopharm, could develop antibodies or monoclonal antibodies that can block the binding of coronavirus to an enzyme known as ACE 2 (Angiotensin-converting enzyme 2).
Share This Post